

# The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy

Andrew M K Law<sup>1,2</sup>, Elgene Lim<sup>3,4</sup>, Christopher J Ormandy<sup>2,4</sup> and David Gallego-Ortega<sup>1,4</sup>

<sup>1</sup>Tumour Development Group, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia

<sup>2</sup>Cancer Biology Laboratory, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia

<sup>3</sup>Connie Johnson Breast Cancer Research Laboratory, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia

<sup>4</sup>St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales Australia, Sydney, New South Wales, Australia

Correspondence should be addressed to D Gallego-Ortega  
**Email**  
[d.gallego@garvan.org.au](mailto:d.gallego@garvan.org.au)

The authors and journal apologise for an error in the above paper, which appeared in volume **24** part 4, pages R123–R144. The error relates to the Funding section on page R135.

The original paper stated:

'DGO is supported by a Garvan Foundation Fellowship generously sponsored by May Dariymple.'

This should have stated:

'DGO is supported by the Garvan Research Foundation and generous donor, Mrs May Dalrymple.'